After receiving $50 M Series D funding, SG’s Mirxes set to list in Hong Kong
After obtaining $50 million in Series D funding, the biotech company Mirxes Holding Company Limited with its headquarters in Singapore revealed on Tuesday that it had submitted an application for listing with The Stock Exchange of Hong Kong Limited.
The Management Committee of the Zhejiang Anji Economic Development Zone indirectly owned a majority stake in Beijing Fupu, according to a statement from Mirxes, which said this Series D funding is supported by both new and existing investors.
Participating in the round were EDB Investments Pte Ltd, wholly owned by the Singapore Economic Development Board, Agency for Science, Technology, and Research, Singapore’s top public sector R&D organization for scientific advancement and technological innovation, Mitsui & Co., Ltd., a business that is listed on several Japanese stock exchanges, and NHH Venture Fund.
The funding, according to the announcement, will be crucial in accelerating Mirxes’s delivery of innovative cancer early detection blood tests and preventive healthcare solutions in significant markets.
The additional funding will be primarily used to increase consumer awareness and uptake of Mirxes’ GASTROClearTM blood test for stomach cancer in important Asia-Pacific markets like Southeast Asia, China, and Japan.
Additionally, it will be used to hasten the development and commercialization of Mirxes’s maturing clinical pipeline, which already includes a blood-based colorectal cancer screening test and a multi-cancer early detection test under Project CADENCE. Project CADENCE is an ambitious project to create a single blood test for the early detection of nine cancers with a high mortality rate, powered by the company’s first-in-class RNA technology and other complementary biomarker technologies.
“Amid challenging macro-environment, this new investment further validates the clinical and socio-economic impact of our proprietary miRNA technology platform, and continues to position Mirxes as a frontrunner in the global fight against cancer through early detection,” said Dr. Zhou Lihan, Co-Founder and Chief Executive Officer of Mirxes.
A company called Mirxes uses RNA technology to make diagnostic tools for the early detection of diseases available on a global scale.
In order to address critical unmet clinical needs across the care continuum, the company is committed to being a leading RNA-centric multi-omics technology company. This commitment has pushed the company toward the listing, which will improve opportunities for investors and further strengthen Mirxes’s position on the global stage.
